Sumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sumitomo Mitsui Trust Holdings Inc. trimmed its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,478,562 shares of the company's stock after selling 41,733 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 3.88% of Intellia Therapeutics worth $106,061,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MetLife Investment Management LLC boosted its holdings in Intellia Therapeutics by 54.7% during the first quarter. MetLife Investment Management LLC now owns 37,362 shares of the company's stock valued at $2,715,000 after purchasing an additional 13,209 shares in the last quarter. Rhumbline Advisers boosted its holdings in Intellia Therapeutics by 2.7% during the first quarter. Rhumbline Advisers now owns 98,247 shares of the company's stock valued at $7,140,000 after purchasing an additional 2,620 shares in the last quarter. Cibc World Market Inc. boosted its holdings in Intellia Therapeutics by 47.3% during the first quarter. Cibc World Market Inc. now owns 4,740 shares of the company's stock valued at $344,000 after purchasing an additional 1,522 shares in the last quarter. Blair William & Co. IL boosted its holdings in Intellia Therapeutics by 11.9% during the first quarter. Blair William & Co. IL now owns 10,362 shares of the company's stock valued at $753,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in Intellia Therapeutics during the first quarter valued at approximately $307,000. 88.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wedbush reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Thursday, February 15th. The Goldman Sachs Group downgraded Intellia Therapeutics from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Canaccord Genuity Group boosted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Friday, February 23rd. Finally, Wolfe Research assumed coverage on Intellia Therapeutics in a report on Thursday, February 15th. They issued a "peer perform" rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $67.00.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.00% of the company's stock.

Intellia Therapeutics Stock Down 1.4 %

NASDAQ:NTLA traded down $0.31 during trading hours on Wednesday, hitting $21.50. 1,076,202 shares of the stock were exchanged, compared to its average volume of 1,523,490. The company's 50 day moving average is $27.56 and its two-hundred day moving average is $28.01. Intellia Therapeutics, Inc. has a twelve month low of $21.44 and a twelve month high of $47.48. The company has a market capitalization of $2.07 billion, a P/E ratio of -3.99 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The firm had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same quarter in the prior year, the business earned ($1.40) EPS. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.58 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.